ClinicalTrials.gg
Status unknownNCT00351286Updated Oct 18, 2006

Efficacy Study of Oral L-Citrulline in Patients Taking Simvastatin With Peripheral Arterial Disease

A Phase 2 interventional study of L-citrulline tablets, 1000 mg and Placebo tablets matching L-citrulline tablets in Peripheral Arterial Disease and Intermittent Claudication, sponsored by Angiogenix. Status unknown at 10 sites in Russian Federation. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2006-10-18.

Primary conditionIntermittent ClaudicationRegistry: Peripheral Arterial DiseaseReclassifiedWhy we changed it
Registry
Peripheral Arterial Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Intermittent Claudication
Why
  1. The study's listed conditions name Intermittent Claudication, a narrower term within Peripheral Arterial Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Angiogenix · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2006), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

To prove the combination of L-citrulline with simvastatin leads to greater improvement in the symptoms of peripheral arterial disease (PAD) than simvastatin alone by evaluating oral L- citrulline or placebo against simvastatin for improvement in treadmill walking distance in patients, 40-75 years of age, who have PAD with intermittent claudication.

Read the detailed description

The primary objective of this study is to prove the combination of L-citrulline with simvastatin leads to greater improvement in the symptoms of PAD than simvastatin alone. This will be accomplished by evaluating efficacy of orally administered L-citrulline or placebo against background therapy with simvastatin for improvement in treadmill absolute claudication walking distance (ACWD) in patients, 40-75 years of age, who have PAD with intermittent claudication in Fontaine stage II and symptom-limited treadmill walking distance.

Secondary objectives include comparing the combination therapy to simvastatin alone for improvement in treadmill pain-free walking distance (PFWD) and ischemic window.

Other secondary objectives include evaluating the safety and tolerability of L-citrulline alone or combined with simvastatin in this patient population and assessing the effects of treatment on quality of life (QOL) as measured by two QOL instruments.

02

Conditions studied

  • Peripheral Arterial Disease
  • Intermittent Claudication

Keywords

  • peripheral arterial disease
  • peripheral vascular disease
  • claudication
03

In context

Intermittent Claudication Reclassified

309 studies on the registry are indexed under Intermittent Claudication; 46 are open to participants now.

This study's enrollment of 160 is above the median of 74 across 242 interventional studies indexed under Intermittent Claudication.

Browse Intermittent Claudication studies →

Lead sponsor

Angiogenix is the lead sponsor of 2 studies on the registry; none are open to participants now.

Compared within Intermittent Claudication, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Arterial Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 40-75 years of age
  2. If female, for the past year, surgically sterile (i.e., tubal ligation, hysterectomy), or using an adequate method of (i.e., oral contraceptives, double barrier method, IUD cover, sterilized partner, or other method deemed appropriate by Investigator)
  3. If male capable of fathering children, using an adequate method of birth control (i.e., condom or partner using adequate method of birth control)
  4. Peripheral arterial disease with stable, reproducible, intermittent claudication and symptom-limited treadmill walking distance of at least 6 months duration
  5. Rest ankle-brachial index (ABI) ≤0.90 and 10 mm Hg decrease in ankle pressure 1 minute after completing the ETT
  6. ACWD on a standardized (Skinner-Gardner protocol) ETT ≥50 m (164 feet) but ≤300 m (984 feet) determined by the average result on two consecutive ETTs performed at least 7 days apart during the screening phase (Fontaine stage II)
  7. ACWD variability \<25% between two consecutive ETTs performed at least 7 days apart during the screening phase. The percent variability is calculated by the difference of the two walking distances divided by the greater of the two walking distances multiplied by 100%. If the variability exceeds 25% a third ETT may be performed and the variability between the second and third test used to determine baseline and inclusion criteria
  8. Willingness to receive dietary counseling and follow a low-cholesterol diet during the study
  9. Ability to give written and has signed a written informed consent form approved by the Investigator's Independent Ethics Committee (IEC)

Exclusion criteria

Exclusion Criteria:

  1. Critical limb ischemia (defined as presence of rest pain requiring analgesics for more than 2 weeks or the presence of lower limb ulcers or gangrene)
  2. Coronary artery or peripheral artery angioplasty or surgical limb arterial bypass within the last 3 months
  3. Any previous amputation on the lower limbs
  4. Anticipated requirement of surgical or percutaneous revascularization within 3 months of randomization
  5. Currently participating in a supervised exercise regimen
  6. Stroke, myocardial infarction, or deep-vein thrombosis within the last 3 months
  7. Non-atherosclerotic PAD (e.g., thromboangiitis obliterans)
  8. Known abdominal aortic aneurysm ≥4.5 cm
  9. Unstable angina pectoris within the last 3 months
  10. Congestive heart failure ( Class III or IV) despite treatment
  11. Severe, uncontrolled hypertension (sitting systolic blood pressure >180 mm Hg or sitting diastolic blood pressure >95 mm Hg)
  12. Anemia ( \<10 g/dL in women and 11 g/dL in men) or any bleeding episode within the last year
  13. Abnormal count (platelets >150,000/mm3 or \<60,000/mm3)
  14. Type I diabetes mellitus or Type II diabetes mellitus if it is accompanied by diabetic peripheral neuropathy
  15. Morbid obesity ( >40 kg/m2)
  16. Severe renal insufficiency (creatinine >221 µmol/L (2.5 mg/dL))
  17. Severe hepatic insufficiency ( [SGPT] and AST [SGOT] ≥ 3x on two separate tests
  18. Any disorder that would affect the interpretation of ETT results
  19. Use of medications that are not allowed and which cannot be discontinued during the study
  20. Participation in an drug or device study within previous 30 days
  21. Underlying disease other than PAD resulting in a of less than 1 year
  22. If female, breast feeding, pregnancy confirmed by a positive serum pregnancy test, or using inadequate
  23. Other conditions that could impair or compliance
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
160 participants

Interventions

  • DrugL-citrulline tablets, 1000 mg
  • DrugPlacebo tablets matching L-citrulline tablets
  • DrugBackground simvastatin at a stable dose of 40 mg qHS
06

What researchers measure

Primary outcomes

  1. Change in absolute claudication walking distance from baseline to end of 12-week double-blind treatment period.

Secondary outcomes

  1. Change in pain-free walking distance

  2. Changes in QOL scores from baseline to 12 and 36 weeks

  3. Change in absolute claudication walking distance from baseline to 36 weeks

07

Study locations

10 sites
  • Municipal Healthcare Institution, Gatchina Central District Hospital
    Gatchina, Russia 188300, Russian Federation
  • Russian State Medical University at Filatov City Hospital #15
    Moscow, Russia 111539, Russian Federation
  • Vishnevsky Institute of Surgery, Russian Medical Academy of Science
    Moscow, Russia 113811, Russian Federation
  • Municipal Prophylaxis and Treatment Institution, City Hospital #13
    N. Novgorod, Russia 603018, Russian Federation
  • Municipal Medical Institution City Hospital #1 of Saratov
    Saratov, Russia 410056, Russian Federation
  • St. Petersburg State Healthcare Institution, Research for Emergency Medical Care
    St. Petersburg, Russia 192242, Russian Federation
  • St. Petersburg State Healthcare Institution, Hospital #2
    St. Petersburg, Russia 194354, Russian Federation
  • St. Petersburg State Healthcare Institution, Hospital #26
    St. Petersburg, Russia 196247, Russian Federation
  • State Educational Institution of Higher Professional Education
    St. Petersburg, Russia 197089, Russian Federation
  • St. Petersburg State Healthcare Institution, Pokrovskaya Hospital
    St. Petersburg, Russia 199106, Russian Federation
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 18, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00351286
Lead sponsor
Angiogenix
First posted
Jul 12, 2006
Start date
Mar 2006
Last update
Oct 18, 2006

Study contacts

William Spickler, MD, PhD
study chair · Angiogenix
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion